BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Biohaven Stock Surges Over 6% on Regulatory Progress for Neurological Drug
Biohaven Stock Surges Over 6% on Regulatory Progress for Neurological Drug
17
1
BTCCSquare news:
Biohaven Pharmaceutical's shares climbed more than 6% in a single trading session after the company received regulatory clarity from the FDA regarding its New Drug Application for troriluzole. The therapy targets spinocerebellar ataxia, a group of debilitating neurological movement disorders.
The FDA's decision to forgo an advisory committee meeting suggests the review process is advancing, though the ultimate approval remains uncertain. Investors are treating the development as a positive signal, propelling the stock's outperformance against broader market indices.
By:
